8-K: Surrozen Announces Positive Phase 1a Data for SZN-043 and Plans Phase 1b Trial in Alcohol-Associated Hepatitis

Surrozen's SZN-043 demonstrated acceptable safety and promising pharmacodynamic effects in a Phase 1a trial, leading to the initiation of a Phase 1b trial for severe alcohol-associated hepatitis.

Summary

• Surrozen has completed a Phase 1a clinical trial for SZN-043, a drug targeting the Wnt pathway for tissue regeneration.
• The trial included 48 subjects, consisting of 40 healthy volunteers and 8 patients with cirrhosis.
• SZN-043 showed acceptable safety and tolerability across all subjects, with no serious adverse events reported.
• The drug demonstrated target engagement, activation of the Wnt signaling pathway, and positive effects on liver function.
• Based on these results, Surrozen is initiating a Phase 1b proof-of-concept trial for severe alcohol-associated hepatitis.
• The Phase 1b trial is expected to have data available in the first half of 2025.
• Surrozen also has a partnership with Boehringer Ingelheim for SZN-413, a drug for retinal diseases, which includes a potential $10 million milestone payment in 2024.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial results and a clear path forward for SZN-043, along with a significant partnership for SZN-413. The sentiment is optimistic due to the potential for addressing unmet medical needs and the validation of their technology.

Positives

• SZN-043 showed a good safety profile in the Phase 1a trial, with no serious adverse events reported.
• The drug demonstrated clear pharmacodynamic activity, indicating it is engaging its target and activating the Wnt pathway.
• Positive effects on liver function were observed in patients with cirrhosis.
• The company is moving forward with a Phase 1b trial in a high-need area, severe alcohol-associated hepatitis.
• The partnership with Boehringer Ingelheim provides non-dilutive funding and validation of their technology.
• Preclinical data for SZN-043 shows rapid stimulation of hepatocyte proliferation and improved liver function.

Negatives

• Some healthy volunteers experienced mild to moderate, transient transaminase elevations, though these resolved without intervention.
• The Phase 1b trial is still in the early stages, and success is not guaranteed.
• The company is reliant on external funding and partnerships to advance its pipeline.

Risks

• The success of clinical trials is not guaranteed, and results may not meet expectations.
• The company may face challenges in securing additional funding for its research and development efforts.
• Regulatory approvals are not guaranteed, and the timeline for commercialization may be uncertain.
• There are risks associated with the volatility in global economic, political, regulatory and market conditions.
• The company is reliant on the success of its partnerships, and any issues with these partnerships could impact the company's progress.

Future Outlook

Surrozen anticipates presenting Phase 1a data at an upcoming medical conference and expects proof-of-concept data from the Phase 1b trial in severe alcohol-associated hepatitis to be available in the first half of 2025. They also expect a potential $10 million milestone payment from Boehringer Ingelheim in 2024.

Management Comments

• Craig Parker, President and Chief Executive Officer of Surrozen, stated that they are excited to have observed activation of Wnt signaling, target engagement and improvement in markers of liver function during the Phase 1a studies.
• Craig Parker also mentioned that they are pleased to advance SZN-043 into the Phase 1b clinical trial in severe alcohol-associated hepatitis.
• He also noted that they look forward to presenting the encouraging Phase 1a data at an upcoming medical conference.

Industry Context

This announcement is significant as it highlights progress in the development of novel therapeutics targeting the Wnt pathway, which is a promising area for regenerative medicine. The focus on severe alcohol-associated hepatitis addresses a significant unmet medical need, and the partnership with Boehringer Ingelheim validates Surrozen's technology and approach in the ophthalmology space.

Comparison to Industry Standards

• The development of SZN-043 for severe alcohol-associated hepatitis is notable as there are currently no approved drugs for this condition, with steroids being used in a minority of cases without significant impact on mortality.
• The use of MELD and Lille scores as endpoints in the Phase 1b trial is consistent with industry standards for assessing liver disease severity and treatment efficacy.
• The partnership with Boehringer Ingelheim for SZN-413 is comparable to other biotech collaborations where larger pharmaceutical companies license promising early-stage assets.
• The potential for Breakthrough Therapy Designation for SZN-043 is a positive sign, as it could expedite the regulatory review process, similar to other drugs that have received this designation for unmet medical needs.
• The focus on Wnt pathway modulation is a novel approach, differentiating Surrozen from companies focusing on more traditional drug targets.

Stakeholder Impact

• Shareholders: The positive clinical trial results and partnership news are likely to be viewed favorably by investors.
• Patients: The development of SZN-043 offers hope for a new treatment option for severe alcohol-associated hepatitis.
• Employees: The progress in clinical trials and partnerships can boost employee morale and job security.
• Partners: The partnership with Boehringer Ingelheim is a positive development for both companies.

Next Steps

• Initiation of the Phase 1b clinical trial for SZN-043 in severe alcohol-associated hepatitis.
• Presentation of Phase 1a data at an upcoming medical conference.
• Continued development of SZN-413 in partnership with Boehringer Ingelheim.
• Potential nomination of a lead development candidate for Fuchs Endothelial Corneal Dystrophy.
• Further preclinical studies in cornea, retina and lung.

Key Dates

Keywords

SZN-043, SZN-413, Wnt pathway, liver regeneration, alcohol-associated hepatitis, retinal diseases, clinical trial, pharmacodynamics, Boehringer Ingelheim, tissue regeneration